[A20-52] Ivacaftor (cystic fibrosis, 6 months to < 18 years, with R117H mutation)- Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2020
Commission awarded on 07.07.2020 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Patients with cystic fibrosis aged 6 months to < 18 years with R117H mutation in the CFTR gene
Neither positive nor negative effects; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.